MedTrace Logo

The Effect of Consumed Berries on Extracellular Vesicle Signalling in the Body

NCT07381933 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-06-09

No results posted yet for this study

Summary

This study examines how berry consumption influences the signaling and distribution of extracellular vesicles (EVs) in the human body. EVs are small bilipid-layered nanoparticles released by cells. EVs carry proteins, lipids, and genetic material, and play a key role in cell-to-cell communication. The composition of EVs reflects the state of their cells of origin, and EVs can affect other cells by delivering their biological contents. EVs offer significant potential for both diagnostics and new therapies.

Recent research has shown that EVs can be found in blood, urine, sweat, and can even cross biological barriers such as the blood-brain barrier and placenta. Many living organisms, including mammalian cells, bacteria, and plants, release EVs. Berries such as cloudberries and lingonberries have demonstrated positive effects on gut microbiota and metabolism, supporting digestive and metabolic health.

In this study, a nutritional intervention will be conducted to investigate the effects of berry consumption on extracellular vesicle signaling of human cells and the gut microbiota, as well as the biodistribution of berry-derived vesicles in the human body.

Conditions

  • Healthy
  • Extracellular Vesicles

Interventions

DIETARY_SUPPLEMENT

Cloudberries

Participants consume 270 grams (equivalent of 3 dl) of cloudberries orally twice daily for 7 days.

DIETARY_SUPPLEMENT

Lingonberries

Participants consume 200 grams (equivalent of 3 dl) of lingonberries orally twice daily for 7 days

Sponsors & Collaborators

  • European Innovation Council

    collaborator OTHER

  • University of Oulu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-23
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07381933 on ClinicalTrials.gov